Try
Vanda Pharmaceuticals Inc. Common Stock
VNDAUnited States
5 filed reports · 262 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 844 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 761 | Dec 2025 |
Financial data
262 concepts · 1,605 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial247 concepts · 1,464 facts · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and service excluding depreciation depletion and amortization12 · Dec 2023 to Jun 2026
- Costs and expenses12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment before tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment before tax12 · Dec 2023 to Jun 2026
- Other comprehensive income loss tax portion attributable to parent112 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
- us-gaap:OtherIncome12 · Dec 2023 to Jun 2026
- Cash and cash equivalents at carrying value11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- Deferred income tax expense benefit11 · Dec 2023 to Jun 2026
- Depreciation11 · Dec 2023 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents11 · Dec 2023 to Jun 2026
Segment8 concepts · 80 facts · Dec 2023 to Jun 2026
- Amortization of intangible assets10 · Dec 2023 to Jun 2026
- Cost of goods and service excluding depreciation depletion and amortization10 · Dec 2023 to Jun 2026
- Income tax expense benefit10 · Dec 2023 to Jun 2026
- Net income loss10 · Dec 2023 to Jun 2026
- Research and development expense10 · Dec 2023 to Jun 2026
- Revenue10 · Dec 2023 to Jun 2026
- Selling general and administrative expense10 · Dec 2023 to Jun 2026
- us-gaap:OtherIncome10 · Dec 2023 to Jun 2026
Product6 concepts · 59 facts · Dec 2018 to Jun 2026
- Revenue38 · Dec 2023 to Jun 2026
- Amortization of intangible assets9 · Dec 2023 to Dec 2025
- Possible future milestone payment5 · Sep 2025 to Jun 2026
- Payments to acquire intangible assets3 · Dec 2018 to Dec 2024
- Royalty payable percentage on net sales2 · Dec 2025 to Mar 2026
- Variable consideration that may be subject to dispute2 · Dec 2024 to Dec 2025
Geography1 concepts · 2 facts · Dec 2025
- Net operating loss carryforwards beginning expiration year2 · Dec 2025
Segments
141 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 80 facts
- Product Segments56 · Jun 2024 to Jun 2026
- Product24 · Dec 2023 to Dec 2025
Product or service5 members · 59 facts
- Hetlioz23 · Dec 2018 to Jun 2026
- PONVORY18 · Dec 2023 to Jun 2026
- Fanapt13 · Dec 2023 to Jun 2026
- Nereus3 · Dec 2023 to Dec 2025
- NEREUS2 · Jun 2025 to Jun 2026
Statement geographical2 members · 2 facts
- DC1 · Dec 2025
- United States Excluding District Of Columbia1 · Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Oct 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 6, 2026
- FY2025 Q4Feb 11, 2026
- FY2025 Q3Oct 29, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.